Gilead Sciences

ASH: Gilead touts 'astounding' Yescarta survival results at 3 years
ASH: Gilead touts 'astounding' Yescarta survival results at 3 years
Fierce Pharma
Gilead Sciences
Yescarta
ASH2019
CAR-T
refractory large B-cell lymphoma
Flag link:
Activists seek to block a Gilead patent extension on a lucrative HIV drug
Activists seek to block a Gilead patent extension on a lucrative HIV drug
Stat
Gilead Sciences
patents
HIV
activists
TAF
Flag link:
Gilead’s converting Truvada PrEP users to Descovy faster than expected: analyst
Gilead’s converting Truvada PrEP users to Descovy faster than expected: analyst
Fierce Pharma
Gilead Sciences
HIV
PrEP
Truvada
Descovy
Flag link:
Amarin for $20B? Novartis' MedCo deal drives fresh buyout rumors for Vascepa's maker
Amarin for $20B? Novartis' MedCo deal drives fresh buyout rumors for Vascepa's maker
Fierce Pharma
Amarin
M&A
Novartis
Medicines Company
Gilead Sciences
Flag link:
Does Amarin Have a Dark Horse Suitor?
Does Amarin Have a Dark Horse Suitor?
Motley Fool
Amarin
Vascepa
M&A
Gilead Sciences
Flag link:
Gilead CEO Daniel O'Day says company is in an 'acquisitive mode'
Gilead CEO Daniel O'Day says company is in an 'acquisitive mode'
Stat
Gilead Sciences
Daniel O'Day
Pharma CEOs
M&A
Flag link:
Will Its HIV Lineup Save Gilead Sciences?
Will Its HIV Lineup Save Gilead Sciences?
Motley Fool
Gilead Sciences
HIV
Descovy
Biktarvy
Flag link:
AASLD: Gilead wants to move the needle for fatty liver therapies
AASLD: Gilead wants to move the needle for fatty liver therapies
Fierce Biotech
Gilead Sciences
NASH
selonsertib
clinical trials
AASLD
Flag link:
HHS sues Gilead for refusing to reach a licensing deal over patents for HIV prevention pills
HHS sues Gilead for refusing to reach a licensing deal over patents for HIV prevention pills
Stat
Gilead Sciences
HIV
HHS
Truvada
Descovy
Flag link:
Gilead’s Matthew Sause to Join Roche Diagnostics as North America CEO
Gilead’s Matthew Sause to Join Roche Diagnostics as North America CEO
Xconomy
Roche Diagnostics
Matthew Sause
Gilead Sciences
Flag link:
Merck loses bid to revive $2.54 billion patent verdict against Gilead
Merck loses bid to revive $2.54 billion patent verdict against Gilead
Yahoo/Reuters
Merck
Gilead Sciences
patents
hepatitis C
Flag link:
Bay Area Life Sciences Professionals Weigh In on Their Ideal Employers
Bay Area Life Sciences Professionals Weigh In on Their Ideal Employers
BioSpace
San Francisco
Bay Area
Genentech
Gilead Sciences
Roche
Amgen
Flag link:
What to make of Gilead's latest NASH deal
What to make of Gilead's latest NASH deal
Biopharma Dive
Gilead Sciences
Glympse Bio
biomarkers
NASH
Flag link:
State-Pharma Deals for Hepatitis C Drugs Come Under Scrutiny
State-Pharma Deals for Hepatitis C Drugs Come Under Scrutiny
BioSpace
hepatitis C
Washington state
AbbVie
Louisiana
Gilead Sciences
Asegua Therapeutics
Flag link:
Gilead’s filgotinib fails midphase tests in lupus, Sjogren's
Gilead’s filgotinib fails midphase tests in lupus, Sjogren's
Fierce Biotech
Gilead Sciences
filgotinib
lupus
Sjögren’s syndrome
clinical trials
Flag link:
Gilead third-quarter results in line, but Yescarta sales dip
Gilead third-quarter results in line, but Yescarta sales dip
Yahoo/Reuters
Gilead Sciences
earnings
Yescarta
Flag link:
The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict
The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict
Yahoo/Benzinga
earnings
Eli Lilly
Alexion
Gilead Sciences
Biomarin
Edwards Lifesciences
Baxter International
Integra LifeSciences
Phathom Pharmaceuticals
IPOs
Foamix
Eton Pharmaceuticals
Melinta Therapeutics
Ligand Pharmaceuticals
Flag link:
Will Strong HIV Sales Drive Gilead's (GILD) Q3 Earnings?
Will Strong HIV Sales Drive Gilead's (GILD) Q3 Earnings?
Yahoo/Zacks.com
Gilead Sciences
earnings
Flag link:
AbbVie, Gilead and Allergan 3-peat with September's top pharma TV spending
AbbVie, Gilead and Allergan 3-peat with September's top pharma TV spending
Fierce Pharma
DTC ads
television ads
AbbVie
Humira
Gilead Sciences
Truvada
Allergan
Botox
Flag link:
Gilead, Galapagos share 52-week update on filgotinib
Gilead, Galapagos share 52-week update on filgotinib
Fierce Biotech
Gilead Sciences
Galapagos
filgotinib
clinical trials
rheumatoid arthritis
Flag link:

Pages